Investor Presentaiton
Confident market and business outlook
Demand momentum in our market is expected to continue at a high level. Main drivers are:
→ The underlying growth of the global (bio)pharmaceutical market;
→The reinforcing trend towards injectable drugs (three quarters of the drugs in development are now designed for
an injectable dosage form);
The shift from traditional cleanrooms to the technologically more advanced isolator technology;
The reshoring of pharmaceutical production.
As a consequence, demand for SKAN's equipment, services and consumables will continue, as evidenced by the
well-filled order pipeline.
To accommodate the strong growth, we will - besides North America - further expand production capacity at the
existing sites in Switzerland and Germany.
SKAN Group expects the 2nd half of 2023 to be even stronger than the 1st half in terms of net sales and profitability.
Guidance for the full year 2023 confirmed.
November 2023
SKAN Group AG Investor Presentation
SKAN
22
22View entire presentation